Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa)

Martin Eichler^{1

2}, Daniel Pink^{3

4}, Franka Menge⁵, Jens Jakob⁶, Leopold Hentschel², Stephan Richter¹, Peter Hohenberger⁵, Bernd Kasper⁷, Dimosthenis Andreou^{4

8}, Susanne Singer⁹, Robert Grützmann¹⁰, Diana I Dmytrow¹¹, Karin Arndt¹², Armin Tuchscherer¹³, Peter Reichardt¹⁴, Marit Ahrens¹⁵, Annegret Kunitz¹⁶, Johannes Mohm¹⁷, Martin Bornhäuser^{1

2}, Jochen Schmitt^{2

18}, Markus K Schuler¹

Affiliations

¹ Clinic and Polyclinic for Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
² National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.
³ Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany.
⁴ Sarcoma Center Berlin-Brandenburg, Helios Hospital Bad Saarow, Bad Saarow, Germany.
⁵ Division of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Centre, University of Heidelberg, Mannheim, Germany.
⁶ Clinic for General, Visceral, and Pediatric Surgery, University Hospital Goettingen, Goettingen, Germany.
⁷ Interdisciplinary Tumour Centre, Sarcoma Unit, University Medical Center Mannheim, Mannheim, Germany.
⁸ Department of General Orthopedics and Tumor Orthopedics, University Hospital Munster, Muenster, Germany.
⁹ Institute of Medical Biostatistics, Epidemiology and Informatics, University Hospital Mainz, Mainz, Germany.
¹⁰ Department of Surgery, University Hospital Erlangen, Erlangen, Germany.
¹¹ Hospital Frankfurt Hoechst, Hoechst, Germany.
¹² German Sarcoma Foundation, Woelfersheim, Germany.
¹³ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
¹⁴ Sarcoma Center Berlin-Brandenburg, Helios Hospital Berlin Buch, Berlin, Germany.
¹⁵ Medical Clinic II, University Hospital Frankfurt, Frankfurt, Germany.
¹⁶ Vivantes Hospital, Berlin, Germany.
¹⁷ Onkopraxis, Joint Practice for Hematology and Oncology, Dresden, Germany.
¹⁸ Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.

PMID: 34342924
DOI: 10.1111/ecc.13484

Observational Study

Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa)

Martin Eichler et al. Eur J Cancer Care (Engl). 2021 Nov.

. 2021 Nov;30(6):e13484.

doi: 10.1111/ecc.13484. Epub 2021 Aug 3.

Authors

Affiliations

¹ Clinic and Polyclinic for Internal Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.
² National Center for Tumor Diseases (NCT/UCC), Dresden, Germany.
³ Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany.
⁴ Sarcoma Center Berlin-Brandenburg, Helios Hospital Bad Saarow, Bad Saarow, Germany.
⁵ Division of Surgical Oncology & Thoracic Surgery, Mannheim University Medical Centre, University of Heidelberg, Mannheim, Germany.
⁶ Clinic for General, Visceral, and Pediatric Surgery, University Hospital Goettingen, Goettingen, Germany.
⁷ Interdisciplinary Tumour Centre, Sarcoma Unit, University Medical Center Mannheim, Mannheim, Germany.
⁸ Department of General Orthopedics and Tumor Orthopedics, University Hospital Munster, Muenster, Germany.
⁹ Institute of Medical Biostatistics, Epidemiology and Informatics, University Hospital Mainz, Mainz, Germany.
¹⁰ Department of Surgery, University Hospital Erlangen, Erlangen, Germany.
¹¹ Hospital Frankfurt Hoechst, Hoechst, Germany.
¹² German Sarcoma Foundation, Woelfersheim, Germany.
¹³ Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.
¹⁴ Sarcoma Center Berlin-Brandenburg, Helios Hospital Berlin Buch, Berlin, Germany.
¹⁵ Medical Clinic II, University Hospital Frankfurt, Frankfurt, Germany.
¹⁶ Vivantes Hospital, Berlin, Germany.
¹⁷ Onkopraxis, Joint Practice for Hematology and Oncology, Dresden, Germany.
¹⁸ Center for Evidence-Based Healthcare, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany.

PMID: 34342924
DOI: 10.1111/ecc.13484

Abstract

Objective: We investigated the health-related quality of life (HRQoL) of patients with gastrointestinal stromal tumours (GIST).

Methods: In the multicentre PROSa study, the HRQoL of adult GIST patients was assessed between 2017 and 2019 using the European Organisation for Research and Treatment of Cancer HRQoL questionnaire (EORTC QLQ-C30). We performed group comparisons and multivariate linear regressions.

Results: Among 130 patients from 13 centres, the mean global HRQoL was 63.3 out of 100 points. Higher sores indicate better HRQoL. The highest restrictions were in emotional, social, role functioning, insomnia, fatigue, and pain. In multivariate linear regression, we found no significant differences between patients receiving tyrosine kinase inhibitor (TKI) treatment and those without TKI treatment as well as between patients treated with curative or with palliative intent. Patients who received multiple lines of TKI treatment had the most restrictions, notably in physical (unstandardized regression coefficient [B] = -15.7), role (B = -25.7), social (B = -18.4), and cognitive functioning (B = -19.7); fatigue (B = 15.93); general health (B = -14.23); and EORTC-sum score (B = -13.82) compared to all other patients.

Conclusion: The highest HRQoL restrictions were in GIST patients receiving multiple lines of TKI therapy. Underlying causes need further investigation.

Keywords: clinically important restrictions and symptoms; gastrointestinal stromal tumours; health-related quality of life; observational study; rare disease; tyrosine kinase inhibitors.

PubMed Disclaimer

References

REFERENCES

1. Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., & de Haes, J. C. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376. https://doi.org/10.1093/jnci/85.5.365
1. Atallah, E., Schiffer, C. A., Weinfurt, K. P., Zhang, M.-J., Radich, J. P., Oehler, V. G., Pinilla-Ibarz, J., Deininger, M. W. N., Lin, L., Larson, R. A., Mauro, M. J., Moore, J. O., Ritchie, E. K., Shah, N. P., Silver, R. T., Wadleigh, M., Cortes, J., Thompson, J., Guhl, J., … Flynn, K. E. (2018). Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer, 18(1), 359. https://doi.org/10.1186/s12885-018-4273-1
1. Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., Buonadonna, A., De Álava, E., Dei Tos, A. P., Del Muro, X. G., Dileo, P., Eriksson, M., Fedenko, A., Ferraresi, V., Ferrari, A., … Blay, J. Y. (2018). Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Annuals of Oncology, 29, iv51-iv67. https://doi.org/10.1093/annonc/mdy096
1. Cocks, K., King, M. T., Velikova, G., Martyn St-James, M., Fayers, P. M., & Brown, J. M. (2011). Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of Cancer quality of life questionnaire Core 30. Journal of Clinical Oncology, 29(1), 89-96. https://doi.org/10.1200/JCO.2010.28.0107
1. Dematteo, R. P., Ballman, K. V., Antonescu, C. R., Maki, R. G., Pisters, P. W. T., Demetri, G. D., Blackstein, M. E., Blanke, C. D., von Mehren, M., Brennan, M. F., Patel, S., McCarter, M. D., Polikoff, J. A., Tan, B. R., Owzar, K., & American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. (2009). Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet (London, England), 373(9669), 1097-1104. https://doi.org/10.1016/S0140-6736(09)60500-6

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

111713/German Cancer Aid

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa)

Affiliations

Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa)

Authors

Affiliations

Abstract

References

REFERENCES

Publication types

MeSH terms

Substances

Grants and funding